Evaluation of a Test Dose Strategy for Pharmacokinetically-guided Busulfan Dosing for Hematopoietic Stem Cell Transplant.

08:00 EDT 19th September 2018 | BioPortfolio

Summary of "Evaluation of a Test Dose Strategy for Pharmacokinetically-guided Busulfan Dosing for Hematopoietic Stem Cell Transplant."

Targeted busulfan dosing helps to limit chemotherapy-related toxicity and optimize disease outcomes in hematopoietic stem cell transplant (HCT). The objective of this study was to evaluate busulfan exposure from a pharmacokinetic (PK)-guided dosing strategy utilizing a test dose. This retrospective evaluation included adult patients who underwent HCT at our institution with busulfan-based myeloablative (> 9 mg/kg) conditioning from January 2014 through October 2015. A weight-based test dose of 0.8 mg/kg was used with PK assessments to predict area under the curve (AUC) achieved with weight-based dosing, with a goal AUC of 4800 µM*min (AUC). PK from the test-dose was then used to calculate a PK-guided first myeloablative busulfan dose. PK assessments were also done after the first dose to assess if the goal area under the curve (AUC) had been achieved (AUC). A PK-guided first dose resulted in achievement of target AUC with target ranges of ±10%, ±15%, and ±20% in 50%, 75%, and 94% of patients, respectively. This was an improved rate of target achievement when compared to the 33%, 44%, and 63% of patients that achieved the desired AUC for each target range, respectively, when using weight-based dosing (p = 0.12, 0.004, and <0.001, respectively). The PK-guided strategy also decreased the variability of AUC from 3.6-fold in AUC from the weight-based test doses (2700.8 to 9631 µM*min; SD 1211.6 µM*min) to 1.8-fold in AUC from the PK-guided first doses (3672.1 to 6609.8 µM*min; SD 574.7 µM*min). This reflects a 2-fold improvement in AUC variability with a PK-guided dosing strategy. This is also improved from the 3-fold variability in AUC reported in other studies. Weight and body surface area were significantly associated with the likelihood of AUC being within the ±10% target range (p = 0.04 for both associations). There was no significant association between AUC and death, relapse, or a composite of the two. These results show a significant improvement in target AUC attainment and less interpatient variability with PK-guided dosing utilizing a test dose strategy versus weight-based dosing.


Journal Details

This article was published in the following journal.

Name: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
ISSN: 1523-6536


DeepDyve research library

PubMed Articles [20551 Associated PubMed Articles listed on BioPortfolio]

Accurate Prediction of Initial Busulfan Exposure Using a Test Dose With 2- and 6-Hour Blood Sampling in Adult Patients Receiving a Twice-Daily Intravenous Busulfan-Based Conditioning Regimen.

This study aimed to predict the area under the curve (AUC) of the initial busulfan dose using a test dose with the sparse sampling scheme in adult patients who underwent hematopoietic cell transplant....

Genotype-guided dosing versus conventional dosing of warfarin: A meta-analysis of 15 randomized controlled trials.

Genotype-guided warfarin dosing algorithm is designed to predict the initial and stable dose of warfarin. However, whether this strategy is superior to conventional dosing method has not been consiste...

Novel Implementation of Genotype-Guided Proton Pump Inhibitor Medication Therapy in Children: A Pilot, Randomized, Multisite Pragmatic Trial.

The efficacy of proton pump inhibitor (PPI) medications is highly dependent on plasma concentrations, which varies considerably due to cytochrome P450 (CYP2C19) genetic variation. We conducted a pragm...

Conversion from Vancomycin Trough Concentration-Guided Dosing to Area Under the Curve-Guided Dosing Using Two Sample Measurements in Adults: Implementation at an Academic Medical Center.

The optimal pharmacodynamic parameter for prediction of efficacy of vancomycin is the area under the concentration-time curve (AUC), and current published data indicate that dosing based on vancomycin...

Genotype-guided Warfarin Dosing in Patients with Mechanical Valves: a Randomized Controlled Trial.

The clinical utility of genotype-guided warfarin dosing remains controversial. The objective of this trial was to evaluate the efficacy and safety of genotype-guided warfarin dosing in East Asians.

Clinical Trials [15673 Associated Clinical Trials listed on BioPortfolio]

Allogeneic Transplantation With Dose-Adjusted Busulfan

The primary purpose of this study is to identify the maximum tolerated dose of continuous infusion IV busulfan in conjunction with fludarabine and alemtuzamab plus tacrolimus for GVHD prop...

The Optimization of 5-Fluorouracil Dose by Pharmacokinetic Monitoring in Asian Patients With Advanced Stage Cancer

The purpose of this study is: 1. To determine the proportion of Asian patients achieving a target area under the curve (AUC) of 20-24 mg.h/L using a pharmacokinetically guided 5-fl...

Targeted, Dose-Escalation Busulfan-Etoposide as Prep Regimen

Busulfan and etoposide have been used as preparative therapy for autoSCT (stem cell transplant) in adults with acute myeloid leukemia (AML) at UCSF for the past 10 years. Over this period...

Carbohydrate Antigen 125-guided Therapy in Heart Failure

Preliminary data suggest a potential role for monitoring and up-titrate pharmacological therapy of plasma levels of antigen carbohydrate 125 (CA125) following and admission for acute heart...

PRospective Evaluation Comparing Initiation of Warfarin StrategiEs (PRECISE): Pharmacogenetic-Guided Versus Usual Care

Warfarin (also called Coumadin®) is an anticoagulant drug (blood thinner) given to patients to help prevent blood clots from forming or to help prevent the growth of an existing blood clo...

Medical and Biotech [MESH] Definitions

The process of gaining approval by a government regulatory agency for DIAGNOSTIC REAGENTS AND TEST KITS. This includes any required preclinical or clinical testing, review, submission, and evaluation of the applications and test results, and post-marketing surveillance.

An alkylating agent having a selective immunosuppressive effect on BONE MARROW. It has been used in the palliative treatment of chronic myeloid leukemia (MYELOID LEUKEMIA, CHRONIC), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.

The dose amount of poisonous or toxic substance or dose of ionizing radiation required to kill 50% of the tested population.

A treatment schedule in which the total dose of radiation is divided into large doses.

Personality evaluation based on the scoring of several variables as a result of the subject's responses in perceiving 47 inkblot plates.

Quick Search


DeepDyve research library

Relevant Topics

Stem Cells
Track and monitor developments in stem cell research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry.  BioPort...

Organ transplantation is the moving of an organ from one body to another or from a donor site to another location on the patient's own body, for the purpose of replacing the recipient's damaged or absent organ. The emerging field of regenerative ...

Searches Linking to this Article